Mathew E. Sowa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mathew E. Sowa has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Alan S. Mann
Warp Drive Bio, Inc., Redwood City, CA 94063
1 shared publication- Andrew Good
C4 Therapeutics, Inc., Watertown, Massachusetts
1 shared publication - Andrew J. Phillips
C4 Therapeutics, Inc., Watertown, Massachusetts
1 shared publication Andrew M. Fry
Department of Molecular and Cell Biology, University of Leicester, LE1 7RH Leicester, United Kingdom
1 shared publicationAndrew T. Rajczewski
Warp Drive Bio, Inc., Redwood City, CA 94063
1 shared publicationBrian R. Bowman
Warp Drive Bio, Inc., Redwood City, CA 94063
1 shared publication
Latest Publications
- 28 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 438-452
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289
- 28 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 438-452
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289
- Open Access
- 30 June 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (29) , 17195-17203
Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface
Significance: This manuscript reports on a member of the FK506/rapamycin family, WDB002, and the realization that FKBP-mediated recognition is a genetically programmable modality that enables engagement of topologically flat targets. FKBP-mediated recognition is thus nature’s strategy for drugging the “undruggable.” The surface of FKBP engages three completely unrelated targets—calcineurin, MTOR, and CEP250—with high-target affinity and specificity, using different constellations of amino acid residues. Target specificity is determined solely by the “variable domain” of the bound small molecule alone, suggesting the modality might be generalizable to other undruggable targets through variable domain engineering. Finally, since WDB002 targets CEP250, it may be a promising starting point for developing a treatment for COVID-19.
- 30 June 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (29) , 17195-17203
Open AccessGenomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface
Significance: This manuscript reports on a member of the FK506/rapamycin family, WDB002, and the realization that FKBP-mediated recognition is a genetically programmable modality that enables engagement of topologically flat targets. FKBP-mediated recognition is thus nature’s strategy for drugging the “undruggable.” The surface of FKBP engages three completely unrelated targets—calcineurin, MTOR, and CEP250—with high-target affinity and specificity, using different constellations of amino acid residues. Target specificity is determined solely by the “variable domain” of the bound small molecule alone, suggesting the modality might be generalizable to other undruggable targets through variable domain engineering. Finally, since WDB002 targets CEP250, it may be a promising starting point for developing a treatment for COVID-19.